Neurobiology of D1 dopamine receptors after neonatal-6-OHDA treatment: relevance to Lesch-Nyhan disease.
D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D000818:Animals; D000831:Animals, Newborn; D001522:Behavior, Animal / Q000187:drug effects*; D001552:Benzazepines / Q000008:administration & dosage / Q000378:metabolism; D001921:Brain / Q000187:drug effects* / Q000503:physiopathology; D004298:Dopamine / Q000378:metabolism / Q000502:physiology; D004873:Ergolines / Q000008:administration & dosage / Q000378:metabolism; D006892:Hydroxydopamines / Q000494:pharmacology*; D007926:Lesch-Nyhan Syndrome / Q000503:physiopathology*; D009409:Nerve Crush; D009474:Neurons / Q000145:classification / Q000187:drug effects / Q000502:physiology; D016627:Oxidopamine; D019257:Quinpirole; D011954:Receptors, Dopamine / Q000187:drug effects / Q000502:physiology*; D017447:Receptors, Dopamine D1; D012652:Self Mutilation / Q000188:drug therapy
D001552:Benzazepines; D004873:Ergolines; D006892:Hydroxydopamines; D011954:Receptors, Dopamine; D017447:Receptors, Dopamine D1; D019257:Quinpirole; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D016627:Oxidopamine; D004298:Dopamine